Specialty Pharmacy Partners
CSL Behring is pleased to provide expanded distribution and availability of Zemaira
through our partnerships with leading specialty pharmacies for respiratory patients,
Accredo and Coram (a division of Apria Healthcare). These partnerships help to ensure
that people who rely on Zemaira will have continued access to their therapy.
- For more information about service with Accredo, call 1-866-6-ALPHA1
(866-625-7421) or visit www.accredo.com
- For more information about service with Coram, call 1-866-FOR-A1Pi
(866-367-2174) or visit
www.coramhc.com
Where will I receive infusions?
Depending on your insurance coverage, your personal preference, and what you and
your healthcare provider decide is best for you, you may receive your infusions
in:
- Your home
- A hospital outpatient department
- A freestanding infusion clinic or center
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.